title: Effect of IFN-gamma treatment and in vivo passage of murine tumor cell lines on their sensitivity to lymphokine-activated killer (LAK) cell lysis in vitro; association with H-2 expression on the target cells.
abstract: Interferon-gamma (IFN-gamma) treatment or in vivo passage of the murine YAC-1 lymphoma resulted in reduced sensitivity to in vitro lysis by syngeneic murine spleen cells cultured in rIL-2 (LAK-cells). IFN-gamma treatment also rendered the murine B16 melanoma less sensitive to lysis by syngeneic LAK cells, whereas in vivo passage did not alter LAK sensitivity. The reduction in sensitivity to lysis correlated with enhanced expression of cell surface H-2 on the target cells. The possible role of H-2 was studied with a beta 2-microglobulin-deficient, and thus H-2-deficient, variant of the YAC-1 lymphoma. This variant line remained H-2 negative even after IFN-gamma treatment or in vivo passage, and was highly sensitive to LAK-cell-mediated lysis, even after IFN-gamma treatment or in vivo passage. The present results are discussed in relation to IFN-gamma and in vivo induced modulation of MHC class-1 molecules on target cells and the possible consequences for interaction with activated as well as "natural" effector cells.
authors.affiliation: Department of Immunology, Karolinska Institutet, Stockholm, Sweden.
authors.forename: L
authors.initials: L
authors.lastname: Tsai
authors.forename: C
authors.initials: C
authors.lastname: Ohlén
authors.forename: H G
authors.initials: HG
authors.lastname: Ljunggren
authors.forename: K
authors.initials: K
authors.lastname: Kärre
authors.forename: M
authors.initials: M
authors.lastname: Hansson
authors.forename: R
authors.initials: R
authors.lastname: Kiessling
mesh_terms: D000818:Animals; D002460:Cell Line; D003601:Cytotoxicity Tests, Immunologic; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D005805:Genes, MHC Class I / Q000187:drug effects / Q000276:immunology; D006183:H-2 Antigens / Q000032:analysis*; D007371:Interferon-gamma / Q000494:pharmacology*; D015979:Killer Cells, Lymphokine-Activated / Q000187:drug effects* / Q000276:immunology; D008223:Lymphoma / Q000276:immunology*; D008546:Melanoma, Experimental / Q000276:immunology*; D051379:Mice; D008805:Mice, Inbred A; D008810:Mice, Inbred C57BL; D008979:Moloney murine leukemia virus; D001613:beta 2-Microglobulin / Q000172:deficiency
chemical_list: D006183:H-2 Antigens; D001613:beta 2-Microglobulin; D007371:Interferon-gamma